Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.7%. By the end of trading, Regeneron Pharmaceuticals fell $7.55 (-2.9%) to $254.87 on average volume. Throughout the day, 844,485 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1,112,200 shares. The stock ranged in price between $245.52-$260.47 after having opened the day at $257.43 as compared to the previous trading day's close of $262.42. Other companies within the Drugs industry that declined today were: Apricus Biosciences ( APRI), down 19.7%, Venaxis ( APPY), down 14.9%, Cormedix ( CRMD), down 9.5% and China Pharma ( CPHI), down 7.8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $24.9 billion and is part of the health care sector. The company has a P/E ratio of 34.5, above the S&P 500 P/E ratio of 17.7. Shares are up 52.0% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, ZIOPHARM Oncology ( ZIOP), down 18.1%, Echo Therapeutics ( ECTE), down 14.6%, MannKind Corporation ( MNKD), down 9.9% and TrovaGene ( TROV), down 9.6% , were all gainers within the drugs industry with Pharmacyclics Incorporated ( PCYC) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
null

If you liked this article you might like

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)